Показати скорочений опис матеріалу
dc.contributor.author | Kovalevskaiia, L. | en |
dc.contributor.author | Pakhlevanzade, A. | en |
dc.contributor.author | Ivanchenko, S. | en |
dc.contributor.author | Kupriianova, L. | en |
dc.contributor.author | Volianska, V. | en |
dc.contributor.author | Plakida, A. | en |
dc.contributor.author | Panigrahi, P. | en |
dc.date.accessioned | 2022-10-25T08:18:55Z | |
dc.date.available | 2022-10-25T08:18:55Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Kovalevskaiia L, Pakhlevanzade A, Ivanchenko S, Kupriianova L, Volianska V, Plakida A, Panigrahi P. Cardiovascular Disorders as a Result of COVID-19. Open Access Maced J Med Sci. 2022 Aug 18; 10(B):1862-1868. | en |
dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/11579 | |
dc.description.abstract | Based on the literature data, we present current literature information about frequency, main spectrum, and prognostic value of cardiovascular complications of the SARS-CoV-2 infection. We have highlighted in detail the variants of cardiovascular disorders in the case of patients with SARS-CoV-2 infection caused by concomitant diseases of hypertension, acute coronary syndrome, myocardial infarction, arrhythmias, virus-associated myocarditis, and heart failure. We have described the adverse cardiovascular effects of medicines of different groups used to treat COVID-19 disease and possible medical interactions. We have summarized some current recommendations on cardiotonic and cardioprotective therapy in the case of patients with cardiovascular complications. | en |
dc.language.iso | en | en |
dc.subject | COVID-19 | en |
dc.subject | Cardiovascular complications | en |
dc.subject | Myocardial damage | en |
dc.title | Cardiovascular Disorders as a Result of COVID-19 | en |
dc.type | Article | en |